# US 2026/0098248 A1 · Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098248 A1
- Document ID: US20260098248A1
- Status: Published application
- Kind: A1
- Application number: 19/355,897
- Filed: 2025-10-10
- Published: 2026-04-09
- Earliest claimed: 2019-05-03
- Assignees: Specific Biologics Inc.
- Applicants: Specific Biologics Inc.
- Inventors: David R. EDGELL; Thomas A. MCMURROUGH; Brent E. STEAD; Odisho K. ISRAEL
- Web page: https://patentgrep.com/patent/US20260098248A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- A61K 9/0043: {Nose}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12R 2001/445: Staphylococcus aureus
- C12R 2001/46: Streptococcus {; Enterococcus; Lactococcus}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.

## Claims

### Claim 1

A method for editing DNA of a cell, comprising:
contacting the cell with a nuclease comprising a Cas9 sequence that is at least 99% identical to SEQ ID NO: 13 and comprises a glutamate at an amino acid corresponding to position 10 of SEQ ID NO: 13, wherein the nuclease edits the DNA of the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell is a mammalian cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the DNA comprises genomic DNA.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell comprises cancer or airway cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the editing comprises a nick or a double stranded cut.

### Claim 6 (depends on 1)

The method of claim 1, further comprising contacting the cell with a donor DNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the editing comprises replacing a target site of the DNA with a sequence of the donor DNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the nuclease cleaves phosphodiester bonds upstream and downstream of a target site of the DNA to remove the target site.

### Claim 9 (depends on 1)

The method of claim 1, wherein the editing of the DNA comprises editing a gene of the DNA, the gene comprising a CFTR or EGFR gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein contacting the cell with the nuclease comprises administering a composition comprising the nuclease to a subject, wherein the subject comprises the cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein contacting the cell with the nuclease comprises administering a composition comprising a polynucleotide encoding the nuclease to a subject, wherein the subject comprises the cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method treats a disease of a subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease comprises cancer or cystic fibrosis.

### Claim 14 (depends on 12)

The method of claim 12, wherein the disease comprises non-small cell lung cancer.

### Claim 15 (depends on 12)

The method of claim 12, wherein the nuclease targets and cleaves 10 to 20 nucleotides on either side of a CFTR delta F508 mutation or an EGFR exon 19 mutation.

### Claim 16 (depends on 1)

The method of claim 1, further comprising contacting the cell with a guide RNA.

### Claim 17 (depends on 1)

The method of claim 1, wherein the nuclease is a chimeric nuclease that further comprises an I-TevI sequence coupled with the Cas9 sequence.

### Claim 18 (depends on 17)

The method of claim 17, wherein the I-TevI sequence comprises the amino acid sequence of SEQ ID NO: 6, or a sequence thereof comprising 1, 2 or 3 mutations each selected from the group consisting of: an amino acid substitution, deletion, and insertion.

### Claim 19 (depends on 1)

The method of claim 1, wherein contacting the cell with the nuclease comprises administering a pharmaceutical composition to a subject comprising the cell, the composition comprising a guide RNA or a nucleic acid encoding the guide RNA, and the nuclease or a nucleic acid encoding the nuclease, wherein the nuclease is a chimeric nuclease that further comprises an I-TevI sequence linked to the Cas9 sequence.

### Claim 20 (depends on 19)

The method of claim 19, wherein the administration comprises intravenous administration, injection, or inhalation.

### Claim 21 (depends on 20)

The method of claim 20, wherein the administration comprises inhalation.

### Claim 22 (depends on 20)

The method of claim 20, wherein the administration comprises nebulization.

### Claim 23 (depends on 19)

The method of claim 19, wherein the composition further comprises a lipid nanoparticle.

### Claim 24 (depends on 23)

The method of claim 23, wherein the lipid nanoparticle is about 100 nM in size.

### Claim 25 (depends on 23)

The method of claim 23, wherein the lipid nanoparticle comprises a cationic lipid.

### Claim 26 (depends on 23)

The method of claim 23, wherein the lipid nanoparticle comprises DOPE, MPEG-5000-DMPE, DPPC, cholesterol, DOBA, or a combination thereof.

### Claim 27 (depends on 1)

The method of claim 1, wherein the DNA comprises genomic DNA, the cell is a mammalian cell, the nuclease is a chimeric nuclease that further comprises an I-TevI nuclease domain connected via a peptide linker to the Cas9 sequence, and wherein the method further comprises contacting the cell with a guide RNA that binds the genomic DNA and the Cas9 sequence.
